ATE290014T1 - Festphasen-peptidsynthese - Google Patents

Festphasen-peptidsynthese

Info

Publication number
ATE290014T1
ATE290014T1 AT97939974T AT97939974T ATE290014T1 AT E290014 T1 ATE290014 T1 AT E290014T1 AT 97939974 T AT97939974 T AT 97939974T AT 97939974 T AT97939974 T AT 97939974T AT E290014 T1 ATE290014 T1 AT E290014T1
Authority
AT
Austria
Prior art keywords
peptide synthesis
phase peptide
solid phase
solid
relates
Prior art date
Application number
AT97939974T
Other languages
English (en)
Inventor
Arne Holm
Bjarne Due Larsen
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Application granted granted Critical
Publication of ATE290014T1 publication Critical patent/ATE290014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97939974T 1996-09-09 1997-09-09 Festphasen-peptidsynthese ATE290014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK97196 1996-09-09
PCT/DK1997/000375 WO1998011125A1 (en) 1996-09-09 1997-09-09 Improved solid-phase peptide synthesis and agent for use in such synthesis

Publications (1)

Publication Number Publication Date
ATE290014T1 true ATE290014T1 (de) 2005-03-15

Family

ID=8099561

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97939974T ATE290014T1 (de) 1996-09-09 1997-09-09 Festphasen-peptidsynthese

Country Status (14)

Country Link
US (1) US7348404B2 (de)
EP (1) EP0929567B1 (de)
JP (1) JP4405594B2 (de)
AT (1) ATE290014T1 (de)
AU (1) AU723268B2 (de)
CA (1) CA2265900C (de)
CZ (1) CZ295838B6 (de)
DE (1) DE69732640T2 (de)
DK (1) DK0929567T3 (de)
ES (1) ES2239364T3 (de)
HU (1) HU230354B1 (de)
IL (1) IL128829A (de)
PT (1) PT929567E (de)
WO (1) WO1998011125A1 (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU757658B2 (en) * 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7550425B2 (en) 2000-06-16 2009-06-23 Zealand Pharma A/S Diuretic peptide conjugates
ATE480561T1 (de) 2004-10-19 2010-09-15 Lonza Ag Verfahren zur festphasen-peptidsynthese
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
GB0514071D0 (en) 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
JPWO2007060860A1 (ja) * 2005-11-22 2009-05-07 学校法人日本大学 ピロールイミダゾールポリアミドの固相自動合成
US7622496B2 (en) 2005-12-23 2009-11-24 Zealand Pharma A/S Modified lysine-mimetic compounds
JP5295785B2 (ja) * 2006-02-20 2013-09-18 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
WO2007114454A1 (ja) * 2006-03-29 2007-10-11 Otsuka Chemical Co., Ltd. ペプチドのチオエステル化合物の製造方法
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
ES2502218T3 (es) 2008-12-15 2014-10-03 Zealand Pharma A/S Análogos de glucagón
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
CN103003300B (zh) 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
CA2802897A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
EA201390796A1 (ru) 2011-01-20 2014-07-30 Зилэнд Фарма А/С Применение ацилированного аналога глюкагона
KR20140100947A (ko) 2011-11-03 2014-08-18 질랜드 파마 에이/에스 Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들
KR20140114845A (ko) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
WO2013098408A1 (en) 2011-12-30 2013-07-04 Zealand Pharma A/S Glucagon and cck receptor agonist peptide conjugates
JP2015510505A (ja) 2012-02-03 2015-04-09 ジーランド ファーマ アクティーゼルスカブ グレリン類似体
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
NZ704043A (en) 2012-07-23 2017-07-28 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
US9695214B2 (en) 2013-03-15 2017-07-04 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AR098065A1 (es) 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
ES2749862T3 (es) 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
PT3604333T (pt) 2014-03-11 2021-06-07 Molecular Templates Inc Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
KR102496206B1 (ko) 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
EP3160995A2 (de) 2014-06-26 2017-05-03 Ossianix Inc. Halbsynthetische ammenhai-vnar-bibliotheken zur herstellung und verwendung von verbindungen mit selektiver bindung
EP3212218B1 (de) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip-agonisten-verbindungen und -verfahren
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
WO2016126950A1 (en) 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
GB201506380D0 (en) 2015-04-15 2015-05-27 Serodus Asa Materials and methods for treatment of pulmonary hypertension
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
CN108290923A (zh) 2015-09-17 2018-07-17 麻省理工学院 用于固相肽合成的方法和系统
CA3033082A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104559A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
AU2017373901B2 (en) 2016-12-09 2021-06-03 Zealand Pharma A/S GLP-1/GLP-2 dual agonists
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
IL271245B2 (en) 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
CA3080351A1 (en) 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
BR112020017385A2 (pt) 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
WO2019246288A1 (en) 2018-06-22 2019-12-26 Ossianix, Inc. Anti-cd98hc vnars for crossing the blood brain barrier and type iv vnar libraries
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
US12351642B2 (en) 2018-09-14 2025-07-08 Ossianix, Inc. TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
US11414496B2 (en) 2019-01-23 2022-08-16 Takeda Pharmaceutical Company Limited Anti-CD38 binding domains
US11713347B2 (en) 2019-01-23 2023-08-01 Millennium Pharmaceuticals, Inc. CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
ES3049784T3 (en) 2019-08-27 2025-12-18 Zp Spv 3 K/S Compstatin analogues and their medical uses
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
EP4031162A1 (de) 2019-09-20 2022-07-27 Zealand Pharma A/S Kv1.3-blocker
US20210155671A1 (en) 2019-11-24 2021-05-27 Molecular Templates, Inc. Uses of cd20-binding molecules and additional therapeutic agents
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
EP4126003A1 (de) 2020-03-30 2023-02-08 Zealand Pharma A/S Duale glp-1-/glp-2-agonisten
JP2023538807A (ja) 2020-07-16 2023-09-12 セッドぺー エスぺーヴェー ３ カー／エス 補体因子ｃ３の阻害剤及びそれらの医学的使用
WO2022103769A1 (en) 2020-11-11 2022-05-19 Ossianix, Inc. High affinity human and monkey specific tfr-1 vnars
AU2021399904B2 (en) 2020-12-16 2024-09-05 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
TWI921427B (zh) 2020-12-16 2026-04-11 丹麥商西蘭製藥公司 Glp-1/glp-2雙重促效劑之醫藥組合物
IL301891A (en) 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
EP4294424B1 (de) 2021-02-18 2026-02-11 Zealand Pharma A/S Glp-1/glp-2-dualagonist zur behandlung des kurzdarmsyndroms
US20220306700A1 (en) 2021-03-17 2022-09-29 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
IL305219A (en) 2021-03-23 2023-10-01 Zealand Pharma As Line suppressors 1.3 which have been changed
WO2022260877A1 (en) 2021-06-07 2022-12-15 Ossianix, Inc. Shark vnars for treating covid-19
EP4357358A4 (de) 2021-06-18 2024-11-06 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Glucagonanalog und medizinische verwendung davon
US20250122298A1 (en) 2021-08-17 2025-04-17 Ossianix, Inc. Deimmunized vnar domains and scaffolds
IL311166A (en) 2021-09-03 2024-04-01 Zealand Pharma As dosage regimen
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
IL312600B2 (en) 2022-05-30 2025-12-01 Zealand Pharma As Liquid formulations of amylin analogs
TW202421654A (zh) 2022-09-28 2024-06-01 丹麥商西蘭製藥公司 治療肥胖之方法
EP4604984A1 (de) 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitoren
AU2024223680A1 (en) * 2023-02-15 2026-07-16 Pep19 Rmh Ltd. Food additive and/or food supplement, production method, formulation of functional food and/or food supplement, use
EP4471048A1 (de) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptidinhibitoren des interleukin-23-rezeptors
EP4471049A1 (de) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptidinhibitoren des interleukin-23-rezeptors
WO2025056677A1 (en) 2023-09-15 2025-03-20 Zealand Pharma A/S Dasiglucagon for use in the treatment of congenital hyperinsulinism
IL328733A (en) 2023-12-04 2026-07-01 Zealand Pharma As Amylin analogs to reduce high-fat food intake
WO2025120002A1 (en) 2023-12-04 2025-06-12 Zealand Pharma A/S Petrelintide for reducing weight whilst preserving lean mass
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
US20250381242A1 (en) 2024-06-12 2025-12-18 Invaio Sciences, Inc. Antimicrobial peptides against citrus greening
US20250382332A1 (en) 2024-06-12 2025-12-18 Invaio Sciences, Inc. Novel alpha-factor based peptides with antifungal activity
TW202617172A (zh) 2024-06-20 2026-05-01 丹麥商西蘭製藥公司 方法
WO2026003546A1 (en) 2024-06-27 2026-01-02 Vrg Miniprotein Zrt Potassium ion kv1.3 channel inhibitors
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026052859A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide
WO2026052861A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116666A (de) * 1974-07-30 1976-02-10 Shionogi Seiyaku Kk
US5021550A (en) * 1986-10-07 1991-06-04 Thomas Jefferson University Method for preventing deletion sequences in solid phase synthesis
JP2807287B2 (ja) * 1989-10-13 1998-10-08 株式会社医学生物学研究所 ペプチドおよびその用途
CA2170030A1 (en) * 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
US7176282B1 (en) * 1996-09-09 2007-02-13 Zealand Pharma A/S Solid-phase peptide synthesis and agent for use in such synthesis
AU757658B2 (en) * 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

Also Published As

Publication number Publication date
DK0929567T3 (da) 2005-06-27
US7348404B2 (en) 2008-03-25
EP0929567B1 (de) 2005-03-02
DE69732640T2 (de) 2006-01-12
PT929567E (pt) 2005-07-29
WO1998011125A1 (en) 1998-03-19
HUP0102900A2 (hu) 2002-01-28
DE69732640D1 (de) 2005-04-07
IL128829A (en) 2005-08-31
CA2265900A1 (en) 1998-03-19
US20070004905A1 (en) 2007-01-04
AU4199397A (en) 1998-04-02
EP0929567A1 (de) 1999-07-21
HUP0102900A3 (en) 2002-02-28
JP4405594B2 (ja) 2010-01-27
AU723268B2 (en) 2000-08-24
ES2239364T3 (es) 2005-09-16
CZ80399A3 (cs) 1999-08-11
IL128829A0 (en) 2000-01-31
CA2265900C (en) 2007-07-31
CZ295838B6 (cs) 2005-11-16
JP2001500134A (ja) 2001-01-09
HU230354B1 (hu) 2016-02-29

Similar Documents

Publication Publication Date Title
DE69732640D1 (de) Festphasen-peptidsynthese
DE69729877D1 (de) Mycophenol bisphosponatverbindungen
TR200001985T2 (tr) Kapa reseptörü opioid peptidleri.
ATE270303T1 (de) Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper
ATE233277T1 (de) Cyklische peptide, die an den urokinase-type plasminogen aktivator rezeptor binden
DK1144607T3 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
IL154809A0 (en) Substituted dipeptides as growth hormone secretagogues
TR200000930T2 (tr) Büyüme hormonu sekretagogları.
ATE394482T1 (de) Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
SE9903291D0 (sv) New process
AU580350B2 (en) Process for synthesising peptides
FI953525L (fi) Kemiallinen syntetointimenetelmä fibronektiiniä sitovan proteiinin tai polypeptidin valmistamiseksi
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
HUT55800A (en) Process for producing anticoagulant peptides
DE69227517D1 (de) Produktion von peptid-amiden
EP1123108A4 (de) Isolierte peptide die an hla-b35 moleküle binden
GR3021660T3 (en) Anticoagulant peptides
SE9800865D0 (sv) New Process
SE9604439D0 (sv) New receptor
IT1270613B (it) Lattami biciclici come intermedi per la sintesi di peptidi biologicamente attivi
ATE417105T1 (de) Spleissvariante des kopftrauma induzierten zytoplasmatischen calcium-bindenden proteins
TW200420553A (en) Process for the synthesis of 3, 3a, 6, 6a-tetrahydro-2H-cyclopentan[b]furan-2-one

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0929567

Country of ref document: EP